NCT01270256View on ClinicalTrials.gov

NasoNeb Delivery of an Intranasal Steroid

PHASE4CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

August 31, 2012

Conditions
Perennial Allergic Rhinitis
Interventions
DRUG

Budesonide

Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily

DRUG

Placebo

Placebo delivered intranasally via NasoNeb nebulizer once daily

Trial Locations (1)

60637

University of Chicago, Chicago

Sponsors

Collaborators (1)

MedInvent, LLC
All Listed Sponsors
collaborator

MedInvent, LLC

UNKNOWN

lead

University of Chicago

OTHER